Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report

Anaplastic lymphoma kinase (ALK) rearrangement responds to ALK tyrosine kinase inhibitors (TKIs) in lung cancer. Many cases ultimately acquire resistance to crizotinib. Resistance, including ALK-dominant or ALK non-dominant, mechanisms have been described. Transformation to small-cell lung cancer is...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Onco Targets Ther
Главные авторы: Zhu, You-cai, Liao, Xing-hui, Wang, Wen-xian, Xu, Chun-wei, Zhuang, Wu, Zhong, Li-hua, Du, Kai-qi, Chen, Yan-ping, Chen, Gang, Fang, Mei-yu
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2017
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5499929/
https://ncbi.nlm.nih.gov/pubmed/28721068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S139718
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы